摘要
目的:观察国产吉西他滨联合卡铂治疗老年人晚期非小细胞肺癌(NSCLC)的临床疗效和不良反应。方法:64例患者随机分为两组:A组:吉西他滨1000mg/m2于第1,8天静脉滴注,卡铂(CBP)300mg/m2静脉滴注,第1天。每28天为1周期。B组:CBP300mg/m2静脉滴注,第1天,足叶乙甙(VP-16)80mg/m2于第1～3天静脉滴注,每28天为1周期。治疗2周期后评价疗效和不良反应。结果:64例患者中可评价疗效病例61例。A组30例中,14例(46.7%)达PR;B组31例中,7例(22.5%)达PR,A组疗效显著高于B组(P<0.05)。第二周期后有62例患者可评价不良反应。最常见的不良反应为骨髓抑制,Ⅲ～Ⅳ度血小板和白细胞下降发生率A组分别为22.6%和32.3%,B组均为12.9%。其余不良反应轻微,可耐受。结论:国产吉西他滨联合卡铂治疗老年人晚期非小细胞肺癌(NSCLC)是有效安全的。
Objective： To evaluate the efficacy and safety of domestic Gemcitabine in combination with carboplatin on advanced non-small cell lung cancer in the elderly. Methods： A total of 64 patients with NSCLC were randomized into two groups, i.e. 32 cases in Group A, gemecitabine 1000 mg/ m^2 was infused on D1 and 8 and carboplatin 300mg/m^2 infused on D1, with 28 clays one cycle; There were 32 cases in Group B, and carboplatin 300 mg/m^2 was infused on D1, VP-16 80mg/m^2 given on D1 to D3, with 28 days a cycle. The patient of each groups received at least 2 cycles, then the efficacy and adverse effect were appraised. Results： Sixty-one patients can be included for response rate. PR was observed in 14/30 （46.7%） in group A and 7/31（22.5%） in group B. The response rate in group A was significantly higher than in group B. The toxicity was found in sixty-two patients who received the second cycle of treatment. The main adverse effect were thrombocytopenia （incidence of 22.6% in Group A and 12.9% in Group B, with grade Ⅲ＋Ⅳ） and leukopenia （incidence of 32.3% in Group A and 12.9% in Group B with grade Ⅲ＋Ⅳ）. Conclusion： The domestic Gemcitabine in combination with carboplatin is safe and effective in the treatment on advanced NSCLC in elderly.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2006年第1期35-37,共3页
Chinese Journal of Clinical Oncology
关键词
吉西他滨
卡铂
非小细胞肺癌
Gemcitabine Carboplatin Non-small cell lung cancer
作者简介
通讯作者：王伟ww8160@sohu．com
